ZOLL Expands Temperature Management Portfolio to Include IQool™ System, High-Quality Surface Option


Matt Hogan
ZOLL Medical Corporation
+1 (978) 805-6561
[email protected]



ZOLL Expands Temperature Management Portfolio to Include IQool™ System, High‑Quality Surface Option

July 24, 2023 — CHELMSFORD, MASS. — ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that it has entered into an agreement with BrainCool, a medical device company specializing in temperature management solutions, for the exclusive distribution of the BrainCool™ System/IQool™ System and the IQool™ System Pads in the U.S. and key markets in Europe, and are working towards expanding distribution to select markets in Asia.

The agreement expands ZOLL’s portfolio of temperature management solutions to include both intravascular technology and surface options — providing clinicians with choices for advanced solutions with precise temperature control and intelligent analytics.

The BrainCool™ System (branded the IQool™ System in the United States) is an advanced surface temperature management system with gel-free and adhesive-free pads that maintains fever control and manages patient temperature in critical care settings. The IQool System features an intuitive user interface, programmable protocol settings and acute temperature control.

“Expanding ZOLL’s temperature management offering to include a high-quality surface option supports our mission to improve patient outcomes and help save lives,” stated Christopher Barnabas, President of ZOLL Circulation. “With our Thermogard XP® and Thermogard HQ™ products — the world’s only intravascular temperature management technology — and BrainCool’s IQool System, we now offer a unique combination of solutions that deliver high-quality patient care while recognizing hospitals’ evolving protocols and increased nursing workload.”

More information on ZOLL’s temperature management solutions can be found online.

BrainCool AB (publ) is based in Lund, Sweden, and is listed on Nasdaq First North Growth Market (symbol: BRAIN).

About ZOLL

ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 46,000 employees around the world, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Material, Homes, and Health Care. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals and diagnostic reagents. For more information, visit www.asahi-kasei.com.

Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability.

Copyright © 2023 ZOLL Medical Corporation. All rights reserved. ZOLL is a registered trademark of ZOLL Medical Corporation and/or its subsidiaries in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.